• In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.

      Ricci, Francesca; Murgia, Xabier; Razzetti, Roberta; Pelizzi, Nicola; Salomone, Fabrizio; Helmholtz Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany. (2017-02)
      CHF5633 is a new generation synthetic surfactant containing both SP-B and SP-C analogues developed for the treatment of respiratory distress syndrome. Here, the optimal dose and its performance in comparison to the animal-derived surfactant poractant alfa were investigated.